---
search:
  boost: 3
---

# Gout

This is a subcategory of Analgesic Agents.

## Decision Trees

- [Analgesic Agents - Gout - Mitigare](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUQldMQ1JLVlg4UEJKOUlBOTdYTE1DWlhHRSQlQCN0PWcu){:target="_blank" rel="noopener"}

- [Analgesic Agents - Gout - Colchicine Tablets, Colcrys Tab](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUODMwUDJNWE9MMzBMRDdMVllJWEpBWU9JRCQlQCN0PWcu){:target="_blank" rel="noopener"}

- [Analgesic Agents - Gout - Febuxostat, Allopurinol 200mg](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUOUlUQjlSTUIxNjRaNExLMjZFN0RUNTlZRSQlQCN0PWcu){:target="_blank" rel="noopener"}

- [Analgesic Agents - Gout - Gloperba Susp](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUM0tTRVpKOVNCQUNNQU1OMkhOWDU4UlVXTyQlQCN0PWcu){:target="_blank" rel="noopener"}

- [Analgesic Agents - Gout - Probenecid/Colchicine](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUMUVWMjlORzhKVjk3TEoyQVpXVjM2NVVFRyQlQCN0PWcu){:target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                             | Generic Name                    | Quantity                  | Time (Days)               |
|---------------------------------------|---------------------------------|---------------------------|---------------------------|
| Allopurinol 100, 300 MG <sup>QL</sup> | Allopurinol Tab (all strengths) | 204                       | 102                       |
| Colchicine Tab <sup>PA QL</sup>       | Colchicine Tab (all strengths)  | Determined pursuant to PA | Determined pursuant to PA |
| Colcrys Tab <sup>PA QL</sup>              | Colchicine Tab (all strengths)  | Determined pursuant to PA | Determined pursuant to PA |
| Probenecid <sup>QL</sup>              | Probenecid Tab (all strengths)  | 408                       | 102                       |

### Non-Preferred

| Non-Preferred                       | Generic Name                                 | Quantity                  | Time (Days)               |
|-------------------------------------|----------------------------------------------|---------------------------|---------------------------|
| Allopurinol 200 MG <sup>QL</sup>    | Allopurinol Tab (all strengths)              | 204                       | 102                       |                                    |                           |
| Mitigare <sup>BvG QL ==(Process by NDC)==</sup>          | Colchicine Cap (all strengths)               | Determined pursuant to PA | Determined pursuant to PA |
| Febuxostat                          |                                              |                           |                           |
| Gloperba Susp <sup>QL</sup>         | Colchicine Soln (all strengths)              | Determined pursuant to PA | Determined pursuant to PA |
| Probenecid/Colchicine <sup>QL</sup> | Probenecid w/ Colchicine Tab (all strengths) | Determined pursuant to PA | Determined pursuant to PA |

## Authorizations

**Length of Authorizations** : 365 days except 180 days for Familial Mediterranean Fever

**All Authorizations** : Must be prescribed in accordance with FDA approved labeling

## Criteria

### Clinical PA

Clinical PA Criteria

-   Must have had an inadequate clinical response with an NSAID and oral corticosteroid within the last 30 days for acute gout diagnosis **OR**
-   Must have had an inadequate clinical response of at least ^^30 days^^ with the maximally tolerated xanthine oxidase inhibitor dose for chronic gout diagnosis

### Non-Preferred

Non-Preferred Criteria

-   Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    -   For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
-   Must have had an inadequate clinical response of at least ^^30 days^^ with at least ^^one preferred^^ drug
    -   For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    -   For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Colchicine Capsule (Mitigare)

Additional Colchicine Capsule (Mitigare) Criteria

-   Must have had an inadequate clinical response of ^^30 days^^ with colchicine tablets

### Colchicine Solution (Gloperba)

Additional Colchicine Solution (Gloperba) Criteria

-   Must be unable to swallow tablets or capsules for authorization of colchicine solution

### Subsequent Authorization

Subsequent Authorization Criteria

-   Must provide documentation of patient’s clinical response to treatment and ongoing safety monitoring

**QL** – All colchicine products: 6 doses per claim for acute gout; 2 doses per day for 30 days for chronic gout; 4 doses per day per 30 days for Familial Mediterranean Fever

## Links

[Rph Use Only: Technicians CANNOT deny Prior Authorizations)](https://mygainwell-my.sharepoint.com.mcas.ms/:w:/r/personal/rachel_carpenter_gainwelltechnologies_com/_layouts/15/Doc.aspx?sourcedoc=%7BCD777F63-7F18-4713-8D6A-B043BEE631F5%7D&file=Denial%20Language%20Updated%2009112023.docx&action=embedview&mobileredirect=true&wdStartOn=3&cid=f4472ece-6d4f-4694-b0c5-c150a2f53fea){:target="_blank" rel="noopener"}

[Criteria](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701+UPDL+Criteria_FINAL.pdf#page=8){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701_UPDL_FINAL_ODM.approved.v2.pdf#page=8){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf#overlay-context=drug-coverage){ :target="_blank" rel="noopener"}
